Table 1.
Demographic characteristics of the study population.
| Oncohematological patients vaccinated against influenza (n = 91) |
Oncohematological patients not vaccinated against influenza (n = 91) |
Healthy controls not vaccinated against influenza (n = 91) | |||
|---|---|---|---|---|---|
| Off therapy <6 months (n = 46) | Off therapy 6–24 months (n = 45) | Off therapy <6 months (n = 46) | Off therapy 6–24 months (n = 45) | ||
| Males, n (%) | 27 (58.7) | 25 (55.6) | 28 (60.8) | 24 (53.3) | 54 (59.3) |
| Mean age ± SD (years) | 9.7 ± 4.3 | 10.2 ± 3.7 | 10.1 ± 3.9 | 10.5 ± 3.5 | 9.7 ± 3.4 |
| Type of cancer, n (%) | |||||
| ALL | 34 (73.9) | 33 (73.3) | 36 (78.3) | 34 (75.6) | n.a. |
| HD | 8 (17.4) | 9 (20.0) | 7 (15.2) | 9 (20.0) | n.a. |
| NHL | 4 (8.7) | 3 (6.7) | 3 (6.5) | 2 (4.4) | n.a. |
| Household contacts, mean number ± SD | 3.31 ± 1.01 | 3.97 ± 0.76 | 4.01 ± 1.19 | 3.55 ± 0.69 | 3.80 ± 0.82 |
| At least one household member vaccinated against influenza, n (%) | 21 (45.7)a | 24 (53.3)b | 19 (41.3)a | 20 (44.4)a | 14 (15.4) |
| Exposure to passive smoking, n (%) | 14 (30.4) | 12 (26.7) | 15 (32.6) | 12 (26.7) | 24 (26.3) |
| Urban residence, n (%) | 44 (95.6) | 42 (93.3) | 43 (93.5) | 43 (95.6) | 90 (98.9) |
| Full-time day-care or school attendance, n (%) | 9 (19.6)b,d | 39 (86.7) | 11 (23.9)b,d | 40 (88.9) | 88 (96.7) |
| Respiratory infections in the previous 12 months, mean n ± SD | 3.55 ± 1.43a,c | 1.88 ± 1.99a | 3.90 ± 1.63a,c | 1.73 ± 1.49a | 1.03 ± 1.40 |
| Antibiotic courses in the previous 12 months, mean n ± SD | 3.69 ± 1.10a,c | 1.61 ± 1.01a | 3.99 ± 1.66a,c | 1.82 ± 1.31a | 0.63 ± 0.99 |
| Hospitalisation in the previous 12 months, mean n ± SD | 7 (15.2)a,c | 0 (0.0) | 6 (13.0)a,c | 0 (0.0) | 1 (1.1) |
ALL, acute lymphoblastic leukemia; HD, Hodgkin disease; NHL, non-Hodgkin's lymphoma; n.a., not applicable; SD, standard deviation; ap < 0.05 and bp < 0.0001 vs healthy controls not vaccinated against influenza; cp < 0.05 and dp < 0.0001 vs oncohematological patients off therapy for 6–24 months.